Menarini Asia-Pacific strengthens Men's Health portfolio in China with acquisition of Cialis(R) (Tadalafil) from Lilly

Menarini Asia-Pacific

2021/7/22 14:05



SINGAPORE, July 22, 2021 /PRNewswire=KYODO JBN/ --


- Acquisition of Cialis(R) in the People's Republic of China to bolster

Menarini's Men's Health portfolio and drive multichannel coverage


-This is a significant milestone for Menarini Asia operations as it

commemorates its 10th anniversary of being established in 13 major healthcare

markets in Asia-Pacific


A. Menarini Asia-Pacific Holdings Pte. Ltd., part of the Menarini Group, the

world's largest Italian biopharmaceutical company, announced today the

completion of its acquisition of Cialis(R) in the People's Republic of China

from Eli Lilly and Company. Through the acquisition, Menarini will take over

ownership of the brand and assume all sales, marketing and distribution



Cialis(R) was first approved by the European Medicines Agency in 2002 followed

by the U.S. Food and Drug Administration ("FDA") in 2003 and then NMPA

(National Medical Products Administration) in 2005, as well as in more than 120

other countries.


With Cialis(R), Menarini intends to strategically expand its nationwide

coverage across the Retail, E-Commerce and Hospital channels and deliver on its

growth ambition in the second-largest healthcare market worldwide. Besides

Men's Health, Menarini is focused on major therapeutic categories including

Dermatology, Allergy/Respiratory, Cardiovascular, Gastroenterology, Pain

Management, Consumer Healthcare, Oncology and Anti-Infectives.


Maurizio Luongo, Chief Executive Officer, Menarini Asia-Pacific said, "The

acquisition of Cialis(R) is a testament to Menarini's commitment to invest and

grow our well diversified Primary and Speciality Care portfolio in the

Asia-Pacific region, which is an increasingly important engine of growth for

the Group. We are excited to take the brand from strength to strength in China

with our well proven, multi-pronged go-to-market strategy for our Men's Health

portfolio in China. We look forward to harnessing the combined strengths of the

complementary products in this portfolio to invigorate lives and relationships

across the nation."


About Cialis(R)(Tadalafil)


Cialis is indicated in China for the treatment of men with erectile dysfunction

(ED), and men with both ED and the signs and symptoms of benign prostatic



Cialis is not for women or children.


It is important to note that Cialis is not to be taken with medicines called

"nitrates" such as nitroglycerin, as tadalafil may potentiate the hypotensive

effect of nitrates; and also GC stimulator, such as riociguat. PDE5 inhibitors,

including tadalafil may potentiate the hypotensive effects of GC stimulators;

or if allergic to Cialis or Adcirca (tadalafil), or any of its ingredients.


About Menarini Asia-Pacific


Menarini Asia-Pacific is a member of the Menarini Group, with a heritage of

over 130 years and over 17,000 employees in more than 140 countries. Here in

Asia-Pacific, Menarini's vision is to be a leading provider of important

healthcare brands to improve the lives of people in the region. Menarini

Asia-Pacific operates across the entire commercial value chain, from clinical

development, regulatory approval and product launch to lifecycle management

with a diverse portfolio of proprietary and partnered brands in key therapeutic

fields, including Consumer Health, Dermatology, Allergy/Respiratory,

Gastroenterology, Cardio-metabolic, Anti-infectives, Oncology/Specialty Care

and Men's Health. For the Financial Year 2020, the Menarini Group clocked sales

revenues of US 4.6 billion dollars, of which the Asia Pacific region has grown

to become a dynamic engine of growth for the Group with more than 10% revenue



For more information about Menarini Asia-Pacific, please visit:


SOURCE Menarini Asia-Pacific